ALT Altimmune, Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 12, 2026
$2,74
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$2,5652 haftanın en düşüğü
$6,4452 haftanın en yükseği
Piyasa Değeri (MRQ)
$532M
P/E
-2.7
Hisse Başına Kâr
$-1.00
Gelir
$41.0K
rozetleriniz
52 Haftlık Aralık
$3–$6
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$17
P/E
-2.7
ROE
-45.6%
Net Kâr Marjı
-214861.0%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
ALT Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$2.73
Piyasa Değeri (MRQ)
$532M
P/E
-2.7
Hisse Başına Kâr
$-1.00
Gelir
$41.0K
ROE
-45.6%
D/E Borç/Özsermaye (MRQ)
0.1
52 Haftlık Aralık
$3–$6
ALT Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Hisse bölünmeleri
| Ex-tarihi | Bölünme | Tür |
|---|---|---|
| 14 Eylül 2018 | 1-for-30 | Ters |
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$41.0K2016-12-31 → 2025-12-31
Hisse Başına Kâr$-1.002016-12-31 → 2025-12-31
Serbest Nakit Akışı$-68M2016-12-31 → 2025-12-31
Net kar marjı-214861.0%2016-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | ALT | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E | -2.75Y ort. ≈-5.8 | ≈-5.8 | · | · | |
| P/S (F/S) | 7396.75Y ort. ≈5179.2 | ≈5179.2 | 144.0 | Aşırı değerli | |
| F/D (MRQ) | 1.15Y ort. ≈3.3 | ≈3.3 | 3.1 | Düşük değerli | |
| EV / EBITDA | -0.75Y ort. ≈-3.6 | ≈-3.6 | · | · | |
| Fiyat / Serbest Nakit Akışı (TTM) | -6.95Y ort. ≈-8.4 | ≈-8.4 | · | · | |
| Fiyat / Nakit Akışı (TTM) | -7.05Y ort. ≈-8.1 | ≈-8.1 | · | · | |
| EV / Revenue (EV / Gelir) | 1563.35Y ort. ≈-1759.5 | ≈-1759.5 | · | · | |
| EV / FCF (TTM) | -3.15Y ort. ≈-4.8 | ≈-4.8 | · | · | |
| Price / Tangible Book (Fiyat / Maddi Defter Değeri) | 1.35Y ort. ≈3.4 | ≈3.4 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | ALT | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Operating Margin (Faaliyet Kâr Marjı) | -230461.0%5Y ort. ≈-128401.5% | ≈-128401.5% | -2083.6% | Zayıf | |
| EBITDA Margin (FAVÖK Marjı) | -230461.0%5Y ort. ≈-128338.7% | ≈-128338.7% | -2083.6% | Zayıf | |
| Pretax Margin (Vergi Öncesi Kar Marjı) | -216522.0%5Y ort. ≈-117982.6% | ≈-117982.6% | -8123.7% | Zayıf | |
| Net Profit Margin (Net Kâr Marjı) | -214861.0%5Y ort. ≈-117708.3% | ≈-117708.3% | -1978.2% | Zayıf | |
| ROA | -42.0%5Y ort. ≈-44.1% | ≈-44.1% | -38.2% | Zayıf | |
| ROE | -45.6%5Y ort. ≈-52.4% | ≈-52.4% | -43.9% | Aynı seviyede | |
| ROIC | -36.2% | · | -36.2% | Aynı seviyede |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | ALT | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Borç / Öz Sermaye (MRQ) | 0.15Y ort. ≈0.1 | ≈0.1 | · | · | |
| Cari Oran (MRQ) | 26.85Y ort. ≈14.3 | ≈14.3 | 13.8 | Güçlü likidite | |
| Quick Ratio (Cari Oran) | 18.25Y ort. ≈13.7 | ≈13.7 | 7.0 | Güçlü likidite | |
| Uzun Vadeli Borç / Özkaynak (MRQ) | 0.15Y ort. ≈0.1 | ≈0.1 | · | · |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | ALT | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 105.0%5Y ort. ≈-12.1% | ≈-12.1% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | -83.5% | · | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | -65.3% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | ALT | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.05Y ort. ≈0.0 | ≈0.0 | 0.0 | Aynı seviyede | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$719.30 | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
17.3%
Sonraki Rapor
Kas 04, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 12, 2026 | $-0.12 | $-0.14 | 14.2% |
| 31 Mart 2026 | May 13, 2026 | $-0.18 | $-0.25 | 27.4% |
| 31 Aralık 2025 | $-0.27 | $-0.25 | -10.2% | |
| 30 Eylül 2025 | $-0.21 | $-0.28 | 26.1% | |
| 30 Haziran 2025 | $-0.27 | $-0.33 | 17.2% | |
| 31 Mart 2025 | $-0.26 | $-0.37 | 29.1% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $41.0K | $20.0K | $426.0K | $-68.0K | $4M | $8M | $6M | $10M | $11M | $3M | · | · | |
| R&D Expense | $66M | $82M | $66M | $71M | $75M | $50M | $18M | $18M | $18M | $7M | $5M | $9M | |
| SG&A Expense | $28M | $21M | $18M | $17M | $15M | $13M | $9M | $10M | $8M | $7M | $6M | $11M | |
| Operating Expenses | $95M | $103M | $96M | $88M | $101M | $63M | $27M | $53M | $63M | $14M | $14M | $20M | |
| Operating Income | $-94M | $-103M | $-96M | $-88M | $-97M | $-55M | $-21M | $-43M | $-52M | $-11M | $-3M | $-10M | |
| Interest Expense | · | · | $35.0K | $8.0K | $5.0K | $9.4K | $2.2K | $297.1K | $162.1K | $38.5K | $54.6K | $210.4K | |
| Interest Income | $8M | $8M | $7M | $3M | $203.0K | $322.5K | $843.4K | $226.6K | $47.6K | $1.0K | · | · | |
| Other Non-op | $-190.0K | $48.0K | $166.0K | $-32.0K | $-374.0K | $24.1K | $15.1K | $277.9K | $5.7K | $42.3K | $8.1K | $-762 | |
| Pretax Income | $-89M | $-95M | $-88M | $-85M | $-97M | $-54M | $-21M | $-45M | $-52M | $-11M | $-3M | $-10M | |
| Income Tax | $-681.0K | · | · | $-197.0K | · | $-5M | $-58.5K | $-6M | $-6M | $0 | $61.7K | $61.7K | |
| Net Income | $-88M | $-95M | $-88M | $-85M | $-97M | $-49M | $-21M | $-39M | $-46M | $-11M | $-3M | $-10M | |
| EPS (Basic) | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 | $-1.91 | · | · | · | $2.97 | $-0.05 | $-0.17 | |
| EPS (Diluted) | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 | $-1.91 | · | · | · | $2.95 | $-0.05 | $-0.17 | |
| Shares (Basic) | 88,104,132 | 71,003,399 | 53,246,937 | 46,926,349 | 41,283,498 | 25,637,023 | · | · | · | 65,306,962 | 63,986,013 | 57,535,325 | |
| Shares (Diluted) | 88,104,132 | 71,003,399 | 53,246,937 | 46,926,349 | 41,283,498 | 25,637,023 | · | · | · | 65,657,802 | 63,986,013 | 57,535,325 | |
| EBITDA | $-94M | $-103M | $-96M | $-88M | $-96M | $-55M | $-21M | $-43M | · | $-11M | $-3M | $-10M |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $44M | $37M | $135M | $111M | $190M | $116M | $9M | $34M | $9M | $3M | $16M | $19M | |
| Short-term Investments | $230M | $95M | $63M | $74M | · | $100M | $28M | · | · | $67M | $0 | · | |
| Receivables | · | · | · | · | · | · | · | · | · | · | · | $400.0K | |
| Prepaid Expense | $3M | $2M | $7M | $5M | $8M | $2M | $470.2K | $548.1K | $994.3K | $420.4K | $181.7K | $199.2K | |
| Current Assets | $278M | $137M | $210M | $193M | $204M | $230M | $39M | $39M | $23M | $4M | $17M | $19M | |
| PP&E (Net) | $312.0K | $413.0K | $651.0K | $1M | $1M | $1M | $1M | $1M | $603.1K | $177.9K | $233.7K | $325.8K | |
| PP&E (Gross) | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $1M | $2M | $3M | |
| Accum. Depreciation | $2M | $2M | $2M | $1M | $2M | $2M | $1M | $1M | $951.8K | $905.3K | $2M | $2M | |
| Goodwill | · | · | · | · | · | · | $0 | $0 | · | $19M | $22M | $2M | |
| Intangibles | · | $0 | $0 | $12M | $12M | $13M | $13M | $14M | $39M | $15M | · | · | |
| Other Non-current Assets | $1M | $2M | $363.0K | $615.0K | $872.0K | $977.2K | $128.5K | $183.7K | $238.9K | $22.2K | $53.4K | $53.4K | |
| Total Assets | $280M | $139M | $211M | $207M | $219M | $245M | $54M | $55M | $63M | $38M | $20M | $22M | |
| Accounts Payable | $3M | $211.0K | $2M | $5M | $2M | $612.3K | $18.2K | $372.9K | $129.1K | $2M | $521.1K | $391.4K | |
| Accrued Liabilities | · | · | · | · | · | $11M | $4M | $4M | $4M | $3M | · | · | |
| Short-term Debt | · | · | · | · | · | · | · | $71.6K | $49.7K | $458.6K | · | · | |
| Current Liabilities | $15M | $10M | $12M | $17M | $18M | $12M | $4M | $5M | $4M | $5M | $2M | $3M | |
| Capital Leases | $1M | $1M | $175.0K | $672.0K | $1M | $1M | $1M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | $58.5K | $6M | $442.6K | $380.8K | $319.0K | |
| Other Non-current Liabilities | $6M | $5M | $40.0K | $60.0K | $80.0K | $110.3K | $130.2K | $140.1K | $160.0K | $442.6K | $433.4K | $493.1K | |
| Total Liabilities | $55M | $16M | $17M | $22M | $20M | $19M | $9M | $6M | $14M | $6M | $3M | $4M | |
| Long-term Debt | $34M | · | · | · | · | · | · | $500.0K | $500.0K | $526.0K | · | · | |
| Total Debt | $34M | · | · | $5M | $1M | $2M | $2M | $71.6K | · | · | $0 | $746.1K | |
| Common Stock | $11.0K | $7.0K | $7.0K | $5.0K | $4.0K | $3.7K | $1.5K | $876 | $61 | $692 | $6.4K | $6.4K | |
| Paid-in Capital | $879M | $690M | $665M | $568M | $497M | $417M | $188M | $170M | $122M | $71M | $240M | $239M | |
| Retained Earnings | $-649M | $-561M | $-466M | $-378M | $-293M | $-186M | $-137M | $-117M | $-78M | $-31M | $-224M | $-220M | |
| AOCI | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-8M | $0 | $-229.5K | |
| Stockholders' Equity | $225M | $124M | $194M | $185M | $199M | $226M | $46M | $48M | $39M | $32M | $43M | $18M | |
| Liabilities + Equity | $280M | $139M | $211M | $207M | $219M | $245M | $54M | $55M | $63M | $38M | $20M | $22M | |
| Shares Outstanding | 110,882,735 | 72,352,701 | 70,677,400 | 49,199,845 | 40,993,768 | 37,142,946 | 15,312,167 | 9,078,238 | 608,499 | 6,917,204 | 64,382,086 | 63,603,303 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | $-205.0K | $551.0K | $428.9K | $387.3K | · | · | · | · | · | |
| Stock-based Comp | $16M | $14M | $11M | $8M | $6M | $3M | $1M | $773.2K | $1M | $965.4K | $613.0K | $2M | |
| Deferred Tax | $-681.0K | · | · | · | · | · | $-58.5K | $-6M | $-3M | $61.8K | $61.7K | $61.7K | |
| Restructuring | · | · | · | · | · | · | · | · | · | $0 | $3M | $0 | |
| Other Non-cash | · | · | · | $14M | $13M | $12M | · | · | · | · | · | · | |
| Operating Cash Flow | $-68M | $-80M | $-76M | $-63M | $-78M | $-34M | $-10M | $-9M | $-20M | $-6M | $-3M | $-8M | |
| CapEx | $11.0K | · | $47.0K | $126.0K | $12M | $204.0K | $1.2K | $975.4K | $112.4K | $125.0K | $86.5K | $92.3K | |
| Investing Cash Flow | $-132M | $-28M | $14M | $-73M | $88M | $-72M | $-28M | $-1M | $14M | · | · | · | |
| Debt Issued | $35M | · | · | · | · | · | · | · | · | · | · | · | |
| Net Debt Issued | $35M | · | · | · | · | · | · | · | · | · | · | · | |
| Stock Issued | $174M | $10M | $87M | $56M | $65M | $48M | · | $4M | · | $4M | $973.1K | $18M | |
| Net Stock Activity | $174M | $10M | $87M | $56M | $65M | $48M | · | $4M | · | $4M | $973.1K | $18M | |
| Financing Cash Flow | $207M | $10M | $86M | $57M | $65M | $213M | $13M | $32M | $16M | · | · | · | |
| Net Change in Cash | $7M | $-98M | $24M | $-79M | $74M | $107M | $-25M | $22M | $9M | $138M | $-3M | $8M | |
| Free Cash Flow | $-68M | · | $-76M | $-63M | $-90M | $-35M | $-10M | $-10M | · | $201M | $-3M | $-9M | |
| Levered FCF | · | · | · | $-63M | · | $-35M | $-10M | $-11M | · | · | $-3M | $-9M |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -230461.0% | -515860.0% | -22518.5% | 129029.4% | -2197.4% | -669.5% | -370.0% | -414.6% | · | -6699.0% | · | · | |
| Net Margin | -214861.0% | -475295.0% | -20762.2% | 124577.9% | -2201.4% | -599.2% | -353.7% | -379.2% | · | 115286.4% | · | · | |
| Pretax Margin | -216522.0% | -475295.0% | -20762.2% | 124867.7% | -2201.4% | -665.4% | -354.7% | -438.7% | · | 121929.0% | · | · | |
| EBITDA Margin | -230461.0% | -515860.0% | -22518.5% | 129330.9% | -2184.9% | -665.9% | -370.0% | -414.6% | · | -6699.0% | · | · | |
| ROA | -42.0% | -54.3% | -42.4% | -39.8% | -41.9% | -32.8% | -37.7% | -66.5% | · | 158.5% | -16.4% | -50.9% | |
| ROE | -45.6% | -74.0% | -51.3% | -43.4% | -47.5% | -23.1% | -43.2% | -89.0% | · | 619.4% | -19.7% | -77.8% | |
| ROIC | -36.2% | · | · | -46.1% | · | -21.7% | -45.2% | -76.5% | · | -54.7% | -20.8% | -53.9% |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 18.5 | 13.1 | 17.3 | 11.3 | 11.2 | 19.2 | 10.0 | 8.7 | · | 1.1 | 7.9 | 7.5 | |
| Quick Ratio | 18.2 | 12.6 | 16.3 | 10.8 | 10.4 | 18.0 | 9.5 | 7.4 | · | 1.1 | 7.1 | 7.4 | |
| Debt / Equity | 0.2 | · | · | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | 0.0 | 0.0 | |
| LT Debt / Equity | 0.2 | · | · | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | |
| Interest Coverage | · | · | -2740.8 | -10967.5 | -17134.7 | -5816.7 | -9565.5 | -144.2 | · | · | -62.3 | -48.4 |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | -0.0 | 0.0 | 0.1 | 0.1 | 0.2 | · | 0.0 | · | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.03 | $1.71 | $2.75 | $3.77 | $4.86 | $6.08 | $2.97 | $5.32 | · | $0.29 | $0.26 | $0.29 | |
| Revenue / Share | $0.00 | $0.00 | $0.01 | $-0.00 | $0.11 | · | · | · | · | $0.00 | · | · | |
| Cash Flow / Share | $-0.77 | $-1.12 | $-1.42 | $-1.33 | $-1.90 | · | · | · | · | $3.07 | · | · | |
| Cash / Share | $0.39 | $0.51 | $1.91 | $2.26 | $4.64 | $3.12 | $0.59 | $3.71 | · | $2.27 | $0.24 | $0.29 | |
| EPS (TTM) | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 | $-1.91 | $2.92 | $2.92 | $2.92 | $2.95 | $-0.05 | $-0.17 |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 105.0% | -95.3% | · | · | -46.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | · | -83.5% | -62.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -65.3% | · | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41.0K | $20.0K | $426.0K | $-68.0K | $4M | $8M | $6M | $10M | $11M | $3M | · | · | |
| Net Income TTM | $-88M | $-95M | $-88M | $-85M | $-97M | $-49M | $-21M | $-39M | $-46M | $-11M | $-3M | $-10M | |
| Market Cap | $400M | $522M | $795M | $809M | $376M | $419M | $29M | $19M | · | · | · | · | |
| Enterprise Value | $161M | · | · | $629M | $187M | $205M | $-6M | $-15M | · | · | · | · | |
| P/E | -3.6 | -5.4 | -6.8 | -9.1 | -3.9 | -5.9 | 0.6 | 0.7 | 20.4 | · | · | · | |
| P/S | 9763.1 | 26083.1 | 1866.5 | -11902.0 | 85.1 | 51.2 | 5.0 | 1.8 | · | · | · | · | |
| P/B | 1.8 | 4.2 | 4.1 | 4.4 | 1.9 | 1.9 | 0.6 | 0.4 | · | · | · | · | |
| P / Tangible Book | 1.8 | 4.2 | 4.1 | 4.7 | 2.0 | 2.0 | · | · | · | · | · | · | |
| P / Cash Flow | -5.9 | -6.5 | -10.5 | -12.9 | -4.8 | -12.2 | -3.0 | -2.0 | · | · | · | · | |
| P / FCF | -5.9 | · | -10.5 | -12.9 | -4.2 | -12.1 | -3.0 | -1.8 | · | · | · | · | |
| EV / EBITDA | -1.7 | · | · | -7.2 | -1.9 | -3.8 | 0.3 | 0.3 | · | · | · | · | |
| EV / FCF | -2.4 | · | · | -10.0 | -2.1 | -5.9 | 0.7 | 1.4 | · | · | · | · | |
| EV / Revenue | 3929.7 | · | · | -9250.6 | 42.3 | 25.0 | -1.1 | -1.4 | · | · | · | · | |
| Earnings Yield | -27.7% | -18.6% | -14.8% | -11.0% | -25.7% | -16.9% | 154.5% | 141.8% | 4.9% | · | · | · |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $26.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $37.0K | $362.0K | $6.0K | $21.0K | $-110.0K | $2.0K | |
| R&D Expense | $19M | $16M | $18M | $15M | $17M | $16M | $20M | $20M | $21M | $21M | $17M | $18M | $13M | $17M | $19M | $20M | |
| SG&A Expense | $8M | $8M | $11M | $6M | $6M | $6M | $5M | $5M | $6M | $5M | $4M | $5M | $5M | $5M | $4M | $4M | |
| Operating Expenses | $26M | $24M | $29M | $21M | $23M | $22M | $25M | $25M | $27M | $27M | $34M | $23M | $18M | $22M | $23M | $25M | |
| Operating Income | $-26M | $-24M | $-29M | $-21M | $-23M | $-22M | $-25M | $-25M | $-27M | $-27M | $-34M | $-23M | $-18M | $-22M | $-23M | $-25M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $1.0K | · | $29.0K | $2.0K | $2.0K | $-183.0K | $64.0K | |
| Interest Income | $5M | $3M | $2M | $2M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | |
| Other Non-op | $-25.0K | $-152.0K | $-27.0K | $-86.0K | $-92.0K | $15.0K | $118.0K | $18.0K | $-76.0K | $-12.0K | $20.0K | $14.0K | $113.0K | $19.0K | $-217.0K | $50.0K | |
| Pretax Income | $-23M | $-23M | $-27M | $-19M | $-22M | $-20M | $-23M | $-23M | $-25M | $-24M | $-32M | $-21M | · | · | $-22M | $-24M | |
| Income Tax | · | · | $0 | $0 | $0 | $-681.0K | · | $0 | $0 | $0 | · | $0 | $0 | $0 | $0 | $-197.0K | |
| Net Income | $-23M | $-23M | $-27M | $-19M | $-22M | $-20M | $-23M | $-23M | $-25M | $-24M | $-32M | $-21M | $-16M | $-20M | $-22M | $-24M | |
| EPS (Basic) | $-0.12 | $-0.18 | $-0.26 | $-0.21 | $-0.27 | $-0.26 | $-0.33 | $-0.32 | $-0.35 | $-0.34 | $-0.55 | $-0.39 | $-0.32 | $-0.40 | $-0.47 | $-0.48 | |
| EPS (Diluted) | $-0.12 | $-0.18 | $-0.26 | $-0.21 | $-0.27 | $-0.26 | $-0.33 | $-0.32 | $-0.35 | $-0.34 | $-0.55 | $-0.39 | $-0.32 | $-0.40 | $-0.47 | $-0.48 | |
| Shares (Basic) | 185,443,736 | 124,461,818 | · | 89,418,028 | 81,477,548 | 75,547,746 | · | 71,084,787 | 70,924,371 | 70,801,713 | · | 53,633,354 | 50,691,558 | 50,125,685 | · | 49,286,535 | |
| Shares (Diluted) | 185,443,736 | 124,461,818 | · | 89,418,028 | 81,477,548 | 75,547,746 | · | 71,084,787 | 70,924,371 | 70,801,713 | · | 53,633,354 | 50,691,558 | 50,125,685 | · | 49,286,535 | |
| EBITDA | $-26M | $-24M | · | $-21M | $-23M | $-22M | · | $-25M | $-27M | $-27M | · | $-23M | $-18M | $-22M | · | $-25M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $63M | $98M | $44M | $61M | $183M | $49M | $37M | $31M | $57M | $79M | $135M | $87M | $102M | $105M | $111M | $127M | |
| Short-term Investments | $263M | $234M | $230M | $150M | · | $101M | $95M | $108M | $108M | $103M | $63M | $54M | $58M | $61M | $74M | $74M | |
| Prepaid Expense | $5M | $1M | $3M | $4M | $4M | $3M | $2M | $3M | $3M | $3M | $7M | $8M | $6M | $4M | $5M | $5M | |
| Current Assets | $335M | $335M | $278M | $217M | $188M | $155M | $137M | $146M | $171M | $188M | $210M | $153M | $170M | $173M | $193M | $211M | |
| PP&E (Net) | $60.0K | $208.0K | $312.0K | $337.0K | $364.0K | $384.0K | $413.0K | $446.0K | $483.0K | $544.0K | $651.0K | $765.0K | $882.0K | $1M | $1M | $1M | |
| PP&E (Gross) | · | · | $3M | · | · | · | $3M | · | · | · | $3M | · | · | · | $3M | · | |
| Accum. Depreciation | · | · | $2M | · | · | · | $2M | · | · | · | $2M | · | · | · | $1M | · | |
| Intangibles | · | · | · | · | · | · | · | · | · | · | $0 | · | · | · | · | $12M | |
| Other Non-current Assets | $90.0K | $746.0K | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $299.0K | $363.0K | $425.0K | $483.0K | $546.0K | $615.0K | $682.0K | |
| Total Assets | $527M | $336M | $280M | $218M | $190M | $157M | $139M | $148M | $173M | $188M | $211M | $167M | $183M | $187M | $207M | $225M | |
| Accounts Payable | $1M | $2M | $3M | $5M | $851.0K | $1M | $211.0K | $1M | $3M | $4M | $2M | $3M | $4M | $5M | $5M | $1M | |
| Current Liabilities | $13M | $11M | $15M | $13M | $9M | $10M | $10M | $9M | $15M | $11M | $12M | $12M | $11M | $15M | $17M | $16M | |
| Capital Leases | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $44.0K | $175.0K | $303.0K | $429.0K | $552.0K | $672.0K | $788.0K | |
| Other Non-current Liabilities | $6M | $6M | $6M | $6M | $5M | $16.0K | $5M | $26.0K | $31.0K | $37.0K | $40.0K | $46.0K | $52.0K | $56.0K | $60.0K | $66.0K | |
| Total Liabilities | $53M | $52M | $55M | $33M | $29M | $15M | $16M | $14M | $21M | $15M | $17M | $16M | $16M | $19M | $22M | $20M | |
| Long-term Debt | $35M | $35M | $34M | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $35M | $35M | · | $14M | $14M | · | · | · | · | · | · | $4M | $4M | $4M | · | $5M | |
| Common Stock | $19.0K | $13.0K | $11.0K | $10.0K | $9.0K | $8.0K | $7.0K | $7.0K | $7.0K | $7.0K | $7.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | |
| Paid-in Capital | $1.18B | $961M | $879M | $813M | $770M | $728M | $690M | $676M | $673M | $669M | $665M | $590M | $587M | $571M | $568M | $567M | |
| Retained Earnings | $-695M | $-672M | $-649M | $-622M | $-603M | $-581M | $-561M | $-538M | $-515M | $-491M | $-466M | $-435M | $-414M | $-398M | $-378M | $-356M | |
| AOCI | $-6M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | $-5M | |
| Stockholders' Equity | $474M | $284M | $225M | $186M | $161M | $142M | $124M | $133M | $153M | $173M | $194M | $150M | $168M | $168M | $185M | $205M | |
| Liabilities + Equity | $527M | $336M | $280M | $218M | $190M | $157M | $139M | $148M | $173M | $188M | $211M | $167M | $183M | $187M | $207M | $225M | |
| Shares Outstanding | 194,474,154 | 130,221,154 | 110,882,735 | 95,598,665 | 85,076,300 | 77,825,450 | 72,352,701 | 71,124,407 | 71,046,267 | 70,899,134 | 70,677,400 | 52,858,920 | 52,657,661 | 49,286,710 | 49,199,845 | 49,161,637 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | · | · | $-552.0K | $-505.0K | $-356.0K | · | $-141.0K | |
| Stock-based Comp | $3M | $3M | $5M | $4M | $4M | $4M | $3M | $3M | $4M | $4M | $2M | $3M | $3M | $3M | $2M | $2M | |
| Deferred Tax | · | · | $0 | $0 | $0 | $-681.0K | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | · | · | · | · | $-2M | · | · | |
| Operating Cash Flow | $-24M | $-21M | $-19M | $-12M | $-19M | $-17M | $-18M | $-27M | $-18M | $-16M | $-17M | $-20M | $-19M | $-19M | $-17M | $-15M | |
| CapEx | $32.0K | $21.0K | $1.0K | $0 | · | · | · | · | · | · | $0 | $0 | $-4.0K | $51.0K | $38.0K | $60.0K | |
| Investing Cash Flow | $-221M | $-4M | $-79M | $-149M | $101M | $-5M | $14M | $1M | $-4M | $-40M | $-8M | $4M | $4M | $13M | $981.0K | $-25M | |
| Debt Issued | · | · | $20M | $0 | · | · | · | · | · | · | · | · | · | · | · | · | |
| Stock Issued | $-89.0K | $9M | $62M | $40M | $38M | $35M | · | · | · | · | $73M | $510.0K | · | · | $0 | $32M | |
| Net Stock Activity | · | $9M | · | · | · | $35M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $211M | $78M | $81M | $39M | $52M | $34M | $10M | $266.0K | $-46.0K | $-261.0K | $73M | $588.0K | $13M | $-302.0K | $-43.0K | $32M | |
| Net Change in Cash | $-35M | $54M | $-17M | $-122M | $134M | $12M | $5M | $-26M | $-22M | $-56M | $48M | $-15M | $-2M | $-6M | $-16M | $-8M | |
| Free Cash Flow | · | $-21M | · | · | · | · | · | · | · | · | · | · | · | $-19M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | -417180.0% | -458440.0% | -436300.0% | · | -495340.0% | -534900.0% | -535880.0% | · | -6226.5% | -300116.7% | -103614.3% | · | -1237600.0% | |
| Net Margin | · | · | · | -380280.0% | -442920.0% | -391500.0% | · | -456900.0% | -492800.0% | -487880.0% | · | -5710.2% | -267683.3% | -95590.5% | · | -1175800.0% | |
| Pretax Margin | · | · | · | -380280.0% | -442920.0% | -405120.0% | · | · | · | · | · | -5710.2% | · | · | · | -1185650.0% | |
| EBITDA Margin | · | · | · | -417180.0% | -458440.0% | -436300.0% | · | -495340.0% | -534900.0% | -535880.0% | · | -6226.5% | -300116.7% | -105309.5% | · | -1237600.0% | |
| ROA | -6.4% | -9.2% | · | -10.4% | -12.2% | -11.3% | · | -14.5% | -13.8% | -13.0% | · | -10.5% | -8.2% | -10.2% | · | -10.2% | |
| ROE | -7.2% | -10.6% | · | -11.9% | -14.1% | -12.4% | · | -16.1% | -15.4% | -14.3% | · | -11.6% | -8.9% | -11.4% | · | -11.3% | |
| ROIC | · | · | · | · | · | -14.8% | · | · | · | · | · | · | · | · | · | -11.7% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 26.8 | 29.6 | · | 17.2 | 20.4 | 15.8 | · | 16.9 | 11.3 | 16.5 | · | 12.9 | 14.8 | 11.6 | · | 13.4 | |
| Quick Ratio | 26.1 | 29.3 | · | 16.7 | 19.9 | 15.3 | · | 16.1 | 10.9 | 16.1 | · | 11.9 | 14.0 | 11.1 | · | 12.8 | |
| Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | · | · | · | · | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| LT Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | · | · | · | · | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -26794.0 | · | -777.2 | -9003.5 | -10879.5 | · | -386.8 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.44 | $2.18 | · | $1.94 | $1.90 | $1.83 | · | $1.88 | $2.15 | $2.44 | · | $2.85 | $3.19 | $3.40 | · | $4.17 | |
| Revenue / Share | · | · | · | $0.00 | $0.00 | $0.00 | · | $0.00 | $0.00 | $0.00 | · | $0.01 | $0.00 | $0.00 | · | $0.00 | |
| Cash Flow / Share | · | $-0.17 | · | · | · | $-0.22 | · | · | · | $-0.23 | · | · | · | $-0.39 | · | · | |
| Cash / Share | $0.32 | $0.75 | · | $0.64 | $2.15 | $0.63 | · | $0.44 | $0.80 | $1.11 | · | $1.64 | $1.94 | $2.12 | · | $2.59 | |
| EPS (TTM) | $-0.77 | $-0.92 | · | $-1.07 | $-1.18 | $-1.26 | · | $-1.56 | $-1.63 | $-1.60 | · | $-1.58 | $-1.67 | $-1.77 | · | $-1.90 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $41.0K | $41.0K | · | $20.0K | $20.0K | $20.0K | · | $52.0K | $409.0K | $410.0K | · | $279.0K | $-81.0K | $-79.0K | · | $3M | |
| Net Income TTM | $-92M | $-91M | · | $-84M | $-88M | $-90M | · | $-104M | $-101M | $-93M | · | $-78M | $-81M | $-85M | · | $-87M | |
| Market Cap | $591M | $401M | · | $360M | $329M | $389M | · | $437M | $472M | $722M | · | $137M | $186M | $208M | · | $628M | |
| Enterprise Value | $300M | $104M | · | $164M | $160M | · | · | · | · | · | · | $959.2K | $30M | $47M | · | $430M | |
| P/E | -3.9 | -3.3 | · | -3.5 | -3.3 | -4.0 | · | -3.9 | -4.1 | -6.4 | · | -1.6 | -2.1 | -2.4 | · | -6.7 | |
| P/S | 14419.5 | 9782.5 | · | 18020.3 | 16462.3 | 19456.4 | · | 8398.2 | 1155.2 | 1760.4 | · | 492.6 | -2294.8 | -2632.8 | · | 189.2 | |
| P/B | 1.2 | 1.4 | · | 1.9 | 2.0 | 2.7 | · | 3.3 | 3.1 | 4.2 | · | 0.9 | 1.1 | 1.2 | · | 3.1 | |
| P / Tangible Book | 1.2 | 1.4 | · | 1.9 | 2.0 | 2.7 | · | 3.3 | 3.1 | 4.2 | · | 0.9 | 1.1 | 1.2 | · | 3.3 | |
| P / Cash Flow | · | -19.2 | · | · | · | -23.1 | · | · | · | -44.1 | · | · | · | -10.7 | · | · | |
| EV / Revenue | 7308.8 | 2537.7 | · | 8203.8 | 8023.6 | · | · | · | · | · | · | 3.4 | -371.5 | -590.6 | · | 129.7 | |
| Earnings Yield | -25.3% | -29.9% | · | -28.4% | -30.5% | -25.2% | · | -25.4% | -24.5% | -15.7% | · | -60.8% | -47.3% | -41.9% | · | -14.9% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $41.0K | $20.0K | $426.0K | $-68.0K | $4M |
| Faaliyet Kâr Marjı % | -230461.0% | -515860.0% | -22518.5% | 129029.4% | -2197.4% |
| Net Gelir | $-88M | $-95M | $-88M | $-85M | $-97M |
| Seyreltilmiş Hisse Başı Kâr | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | 0.2 | · | · | 0.0 | 0.0 |
| Cari Oran | 18.5 | 13.1 | 17.3 | 11.3 | 11.2 |
| Cari Oran | 18.2 | 12.6 | 16.3 | 10.8 | 10.4 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-68M | · | $-76M | $-63M | $-90M |
Kurumsal Sahipler (13F) 235 dosya · $501.0M toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
235
Tutulan Değer
$501.0M
Yeni pozisyonlar
61
Çıkan pozisyonlar
17
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 61 (+31 önceki Ç'ye göre) | 17 (-16 önceki Ç'ye göre) | 87 (+3 önceki Ç'ye göre) | 37 (-2 önceki Ç'ye göre) | +81.8M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| BlackRock, Inc. | $61.971.264 | 20.385.284 | 12,37% | Hisse senetleri |
| Deep Track Capital, LP | $58.520.000 | 19.250.000 | 11,68% | Hisse senetleri |
| STATE STREET CORP | $36.779.562 | 12.098.540 | 7,34% | Hisse senetleri |
| VANGUARD GROUP INC | $34.263.084 | 9.491.159 | 6,84% | Hisse senetleri |
| TCG Crossover Management, LLC | $30.400.000 | 10.000.000 | 6,07% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $24.860.366 | 8.177.752 | 4,96% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $22.284.006 | 7.330.265 | 4,45% | Hisse senetleri |
| MARSHALL WACE, LLP | $20.796.808 | 6.841.055 | 4,15% | Hisse senetleri |
| VIKING GLOBAL INVESTORS LP | $20.368.000 | 6.700.000 | 4,07% | Hisse senetleri |
| RA CAPITAL MANAGEMENT, L.P. | $19.760.000 | 6.500.000 | 3,94% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $15.238.163 | 5.011.314 | 3,04% | Hisse senetleri |
| Woodline Partners LP | $10.336.948 | 3.400.312 | 2,06% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $10.059.731 | 3.309.122 | 2,01% | Hisse senetleri |
| Trails Edge Capital Partners, LP | $8.086.400 | 2.660.000 | 1,61% | Hisse senetleri |
| Nuveen, LLC | $7.312.276 | 2.405.354 | 1,46% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $7.238.672 | 2.381.142 | 1,44% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $6.731.928 | 2.214.450 | 1,34% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $5.469.872 | 1.799.300 | 1,09% | Alım opsiyonu |
| GREAT POINT PARTNERS LLC | $5.293.345 | 1.741.232 | 1,06% | Hisse senetleri |
| NORTHERN TRUST CORP | $4.861.648 | 1.599.226 | 0,97% | Hisse senetleri |
| Weiss Asset Management LP | $4.653.641 | 1.530.803 | 0,93% | Hisse senetleri |
| Nantahala Capital Management, LLC | $4.560.000 | 1.500.000 | 0,91% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $3.930.723 | 1.293.001 | 0,78% | Hisse senetleri |
| Cormorant Asset Management, LP | $3.800.000 | 1.250.000 | 0,76% | Hisse senetleri |
| AQR CAPITAL MANAGEMENT LLC | $3.711.686 | 1.220.949 | 0,74% | Hisse senetleri |
| CITADEL ADVISORS LLC | $2.990.019 | 983.559 | 0,60% | Hisse senetleri |
| TWO SIGMA ADVISERS, LP | $2.865.979 | 793.900 | 0,57% | Hisse senetleri |
| UBS Group AG | $2.633.810 | 866.385 | 0,53% | Hisse senetleri |
| MORGAN STANLEY | $2.305.642 | 758.435 | 0,46% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $2.304.074 | 757.919 | 0,46% | Hisse senetleri |
| Ghisallo Capital Management LLC | $2.280.000 | 750.000 | 0,46% | Hisse senetleri |
| FMR LLC | $2.276.881 | 748.974 | 0,45% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $2.222.477 | 731.078 | 0,44% | Hisse senetleri |
| Bank of New York Mellon Corp | $2.096.727 | 689.713 | 0,42% | Hisse senetleri |
| TANG CAPITAL MANAGEMENT LLC | $2.024.707 | 666.022 | 0,40% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $1.943.537 | 639.436 | 0,39% | Hisse senetleri |
| CITADEL ADVISORS LLC | $1.918.240 | 631.000 | 0,38% | Alım opsiyonu |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1.898.477 | 624.499 | 0,38% | Hisse senetleri |
| Point72 Asset Management, L.P. | $1.480.127 | 486.884 | 0,30% | Hisse senetleri |
| Rock Springs Capital Management LP | $1.433.254 | 471.465 | 0,29% | Hisse senetleri |
| Beirne Wealth Consulting Services, LLC | $1.282.449 | 421.858 | 0,26% | Hisse senetleri |
| WELLINGTON MANAGEMENT GROUP LLP | $1.277.712 | 420.300 | 0,26% | Hisse senetleri |
| BNP PARIBAS FINANCIAL MARKETS | $1.128.375 | 371.176 | 0,23% | Hisse senetleri |
| BARCLAYS PLC | $1.068.825 | 351.587 | 0,21% | Hisse senetleri |
| Invesco Ltd. | $1.011.079 | 332.592 | 0,20% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $990.128 | 325.700 | 0,20% | Satım opsiyonu |
| RHUMBLINE ADVISERS | $941.193 | 309.606 | 0,19% | Hisse senetleri |
| LMR Partners LLP | $912.000 | 300.000 | 0,18% | Hisse senetleri |
| CITIGROUP INC | $893.602 | 293.948 | 0,18% | Hisse senetleri |
| Steward Partners Investment Advisory, LLC | $810.680 | 266.671 | 0,16% | Hisse senetleri |
Aktivistler ve %5+ sahipler 18 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management II, LLC, VHCP Management III, LLC, Shah, Nimish, Koh, Bong | 25 Haziran 2020 | · | İlk başvuru | Pasif yatırım | SEC |
| Philip Hodges, Redmont Venture Partners, Inc., Redmont VAXN Capital Holdings, LLC, Paradigm Venture Partners, L.P. ×3 başvurular | 19 Ekim 2017 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 30 Mart 2016 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 12 Şubat 2016 | · | İlk başvuru | · | SEC |
| PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C., PRESCOTT GROUP AGGRESSIVE SMALL CAP, L.P., PRESCOTT GROUP AGGRESSIVE SMALL CAP II, L.P., PHIL FROHLICH ×6 başvurular | 02 Aralık 2013 | · | İlk başvuru | Pasif yatırım | SEC |
| Theraclone Sciences, Inc. | 12 Ağustos 2013 | · | İlk başvuru | M&A / satış | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 27 Aralık 2010 | · | İlk başvuru | Pasif yatırım | SEC |
| Kelisia Holdings L imited, Panacea Biotec Limited | 18 Eylül 2009 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 04 Ağustos 2009 | · | İlk başvuru | Pasif yatırım | SEC |
| HealthCare Ventures VII, L.P., HealthCare Partners VII, L.P., James H. Cavanaugh, Ph.D., John Littlechild, Harold Werner, Augustine Lawlor, Christopher Mirabelli, Ph.D. ×3 başvurular | 03 Ağustos 2009 | · | İlk başvuru | Pasif yatırım | SEC |
| Bear Stearns Health Innoventures, L.P., Bear Stearns Health Innoventures Offshore, L.P., BX, L.P., Bear Stearns Health Innoventures Employee Fund, L.P., BSHI Members, L.L.C., Bear Stearns Health Innoventures Management, L.L.C., Bear Stearns Asset Management Inc. ×3 başvurular | 29 Mayıs 2009 | · | İlk başvuru | Yönetim kurulu kampanyası | SEC |
| Integrated Core Strategies (US) LLC, Riverview Group LLC, Millennium Management LLC, Israel A. Englander ×2 başvurular | 23 Nisan 2009 | · | İlk başvuru | M&A / satış | SEC |
| Nexia Biotechnologies Ltd. | 30 Mayıs 2008 | · | İlk başvuru | Pasif yatırım | SEC |
| Açıklanmayan raporlama kişisi | 17 Ağustos 2007 | · | İlk başvuru | Pasif yatırım | SEC |
| Açıklanmayan raporlama kişisi | 14 Ağustos 2007 | · | İlk başvuru | Pasif yatırım | SEC |
| MPM BioVentures III, L.P., MPM BioVentures III-QP, L.P., MPM BioVentures III GmbH & Co. Beteiligungs KG, MPM BioVentures III Parallel Fund, L.P., MPM Asset Management Investors 2004 BVIII LLC, MPM BioVentures III GP, L.P., MPM BioVentures III LLC, Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon III, Michael Steinmetz, Kurt Wheeler | 14 Ağustos 2007 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 13 Ağustos 2007 | · | İlk başvuru | M&A / satış | SEC |
| QVT Financial LP, QVT Financial GP LLC ×2 başvurular | 07 Ağustos 2007 | · | İlk başvuru | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 49 içeriden öğrenenler · 26 yöneticiler · 21 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Jerome Benedict Durso | President and CEO | 13 Ağustos 2026 P | 62.500 | 4 | 0 | $213.775 |
| William Enright | President and CEO | 25 Mayıs 2018 P | 365.839 | 0 | 0 | $0 |
| David P Wright | President and CEO | 11 Aralık 2009 P | 399.500 | 0 | 0 | $0 |
| Gregory L Weaver | Chief Financial Officer | 31 Temmuz 2026 A | 39.831 | 2 | 0 | $49.200 |
| Andrew Shutterly | Acting Chief Financial Officer | 31 Temmuz 2024 A | 11.372 | 0 | 0 | $0 |
| Richard I Eisenstadt | Chief Financial Officer | 30 Ocak 2024 M | 45.012 | 0 | 0 | $0 |
| William Michael Brown | Chief Financial Officer | 31 Temmuz 2021 A | 17.721 | 0 | 0 | $0 |
| Elizabeth Czerepak | CFO and EVP Corp. Development | 22 Eylül 2017 A | · | 0 | 0 | $0 |
| MACNEILL PHILIP | VP, CFO, Treasurer, Secretary | 21 Aralık 2016 M | 126.346 | 0 | 0 | $0 |
| Linda L Chang | SVP, CFO & Secretary | 07 Ocak 2015 M | 30.000 | 0 | 0 | $0 |
| Charles A. Reinhart III | SVP, Chief Financial Officer | 08 Aralık 2010 A | · | 0 | 0 | $0 |
| Kevin Price | President - PharmAthene UK,Ltd | 21 Ocak 2009 A | 2.500 | 0 | 0 | $0 |
| Jeffrey Michael Jones | COO | 11 Mart 2015 A | 27.544 | 0 | 0 | $0 |
| Richard Thomas Menziuso | Principal Accounting Officer | 01 Ekim 2026 A | · | 0 | 0 | $0 |
| Linda M Richardson | Chief Commercial Officer | 16 Eylül 2026 M | 17.174 | 0 | 0 | $0 |
| Scot M Roberts | Chief Scientific Officer | 31 Temmuz 2026 A | 113.699 | 0 | 0 | $0 |
| Raymond M Jordt | Chief Business Officer | 31 Ocak 2026 A | 70.107 | 0 | 0 | $0 |
| Christophe Arbet-Engels | Chief Medical Officer | 01 Ekim 2025 A | · | 0 | 0 | $0 |
| Matthew Scott Harris | Chief Medical Officer | 31 Temmuz 2025 A | 16.087 | 0 | 0 | $0 |
| Sybil Tasker | Chief Medical Officer | 17 Haziran 2019 A | · | 0 | 0 | $0 |
| Wayne Morges | SVP, Reg. Affairs & Quality | 08 Aralık 2014 A | 35.532 | 0 | 0 | $0 |
| Francesca M Cook | SVP, Policy & Gov't Affairs | 08 Aralık 2014 A | 37.631 | 0 | 0 | $0 |
| Thomas Richard Fuerst | EVP, Chief Scientific Officer | 01 Aralık 2011 A | 15.000 | 0 | 0 | $0 |
| Valerie D Riddle | SVP, Medical Director | 31 Mayıs 2011 M | 44.436 | 0 | 0 | $0 |
| Joan Fusco | SVP, Operations | 06 Mayıs 2010 A | 36.730 | 0 | 0 | $0 |
| Christopher C Camut | VP, Gov't Contracts | 21 Ocak 2010 F | 46.777 | 0 | 0 | $0 |
| Teri L Lawver | Yönetim kurulu üyesi | 01 Mayıs 2026 A | · | 0 | 0 | $0 |
| Wayne Pisano | Yönetim kurulu üyesi | 01 Mayıs 2026 A | 13.498 | 1 | 0 | $20.400 |
| Klaus Schafer | Yönetim kurulu üyesi | 01 Mayıs 2026 A | 9.179 | 0 | 0 | $0 |
| Philip Hodges | Yönetim kurulu üyesi | 01 Mayıs 2026 A | 8.731 | 0 | 0 | $0 |
| Catherine A. Sohn | Yönetim kurulu üyesi | 01 Mayıs 2026 A | 1.500 | 1 | 0 | $2.120 |
| Diane Jorkasky | Yönetim kurulu üyesi | 01 Mayıs 2026 A | 527 | 1 | 0 | $2.003 |
| John Gill | Yönetim kurulu üyesi | 01 Mayıs 2026 A | 21.700 | 2 | 0 | $82.622 |
| Mitchel Sayare | Yönetim kurulu üyesi | 01 Mayıs 2026 A | 26.363 | 0 | 0 | $0 |
| Vipin K Garg | Yönetim kurulu üyesi | 30 Ocak 2026 M | 424.519 | 0 | 0 | $0 |
| David Drutz | Yönetim kurulu üyesi | 19 Ağustos 2024 M | 55.524 | 0 | 0 | $0 |
| SCHAFFER DERACE L | Yönetim kurulu üyesi | 29 Aralık 2017 P | 589.453 | 0 | 0 | $0 |
| Jeffrey W. Runge | Yönetim kurulu üyesi | 20 Ocak 2017 M | 197.700 | 0 | 0 | $0 |
| Steven St Peter | Yönetim kurulu üyesi | 04 Ocak 2017 M | 205.004 | 0 | 0 | $0 |
| Eric I Richman | Yönetim kurulu üyesi | 22 Kasım 2016 M | 898.055 | 0 | 0 | $0 |
| Joel Mccleary | Yönetim kurulu üyesi | 31 Aralık 2014 A | 120.167 | 0 | 0 | $0 |
| Brian A Markison | Yönetim kurulu üyesi | 31 Aralık 2014 A | · | 0 | 0 | $0 |
| John Pappajohn | Yönetim kurulu üyesi | 23 Haziran 2011 A | 394.044 | 0 | 0 | $0 |
| CAVANAUGH JAMES H | Yönetim kurulu üyesi | 23 Haziran 2010 A | · | 0 | 0 | $0 |
| VELOCITY PHARMACEUTICAL HOLDINGS LLC | 10% sahip | 15 Mayıs 2020 S | 1.687.250 | 0 | 0 | $0 |
| Truffle Capital S.A.S. | 10% sahip | 13 Şubat 2018 J | 76.700 | 0 | 0 | $0 |
| ANSBERT GADICKE | 10% sahip | 03 Ağustos 2007 A | · | 0 | 0 | $0 |
| Jordan P Karp | · | 03 Aralık 2012 A | 21.929 | 0 | 0 | $0 |
| Matthew P Kinley | · | 03 Ağustos 2007 P | 541.000 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 24 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0,73% | 119.086 NS | 31 Temmuz 2026 | N-PORT |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,48% | 38.580 SH | 01 Ekim 2026 | Günlük |
| LABU · Direxion Shares ETF Trust | 0,16% | 275.123 NS | 31 Temmuz 2026 | N-PORT |
| IWC · iShares Trust | 0,15% | 673.707 SH | 11 Eylül 2026 | Günlük |
| IBB · iShares Trust | 0,05% | 1.414.762 SH | 11 Eylül 2026 | Günlük |
| PWS · Pacer Funds Trust | 0,04% | 3.759 NS | 31 Temmuz 2026 | N-PORT |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,04% | 172.834 SH | 19 Ağustos 2026 | Günlük |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,04% | 13.762 SH | 01 Ekim 2026 | Günlük |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,02% | 207.080 SH | 01 Ekim 2026 | Günlük |
| IWM · iShares Trust | 0,02% | 5.067.516 SH | 11 Eylül 2026 | Günlük |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 1.142.675 SH | 19 Ağustos 2026 | Günlük |
| RSSL · Global X Funds | 0,02% | 94.969 NS | 31 Temmuz 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 2.235.429 SH | 19 Ağustos 2026 | Günlük |
| VHT · VANGUARD WORLD FUND | 0,01% | 569.267 SH | 19 Ağustos 2026 | Günlük |
| DFAS · Dimensional ETF Trust | 0,00% | 167.692 NS | 31 Temmuz 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 358.632 SH | 11 Eylül 2026 | Günlük |
| DCOR · Dimensional ETF Trust | 0,00% | 8.167 NS | 31 Temmuz 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 23.537 SH | 03 Eylül 2026 | Günlük |
| DFUS · Dimensional ETF Trust | 0,00% | 25.408 NS | 31 Temmuz 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 9.653 NS | 31 Temmuz 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,00% | 34.439 NS | 31 Temmuz 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 5.748.771 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 16.865 SH | 19 Ağustos 2026 | Günlük |
| IWN · iShares Trust | · | 1.858.292 SH | 11 Eylül 2026 | Günlük |
ALT Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 15 analist
AL
Medyan hedef
$17.00
+521,6%
4 26,7%
Güçlü Al
9 60,0%
Al
2 13,3%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
9 analist · 2026-09-30Ortalama hedef $17.11 +525,6%
← Tüm hedeflerin altında
Mevcut fiyat $2.73
Düşük$11.00
Ortalama$17.11
Yüksek$28.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| ALT | $400M | -3.6 | 105.0% | -214861.0% | -45.6% | · |
| IRWD | $550M | 22.5 | -15.7% | 8.1% | -8.5% | · |
| SGMT | · | -3.7 | · | · | -42.3% | · |
| CTMX | $725M | · | -44.8% | -22.8% | -15.9% | · |
| PRME | $626M | -2.6 | 55.3% | -4342.4% | -221.4% | · |
| ALLO | $314M | -1.6 | -76.8% | · | -59.9% | · |
| MPLT | $773M | -0.9 | · | · | -151.1% | · |
| MNPR | · | · | · | · | · | · |
| CBIO | $327M | -24.2 | -86.7% | -1419.6% | -90.0% | · |
| NGNE | $319M | -4.9 | · | · | -33.6% | · |
| ZURA | · | · | · | · | · | · |
Son Haberler Bu şirketten bahseden son manşetler
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 12, 2026